Today’s Stock On Watch: Could Heska Corp See a Reversal After Breaking Its 52-Week High?

Today's Stock On Watch: Could Heska Corp See a Reversal After Breaking Its 52 Week High?

The stock of Heska Corp (NASDAQ:HSKA) hit a new 52-week high and has $98.97 target or 62.00% above today’s $61.09 share price. The 6 months bullish chart indicates low risk for the $477.23M company. The 1-year high was reported on Nov, 7 by Barchart.com. If the $98.97 price target is reached, the company will be worth $295.88 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 57,530 shares traded hands. Heska Corp (NASDAQ:HSKA) has risen 102.62% since April 5, 2016 and is uptrending. It has outperformed by 100.67% the S&P500.

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on November, 9. They expect $0.26 earnings per share, up 30.00% or $0.06 from last year’s $0.2 per share. HSKA’s profit will be $2.03M for 58.74 P/E if the $0.26 EPS becomes a reality. After $0.35 actual earnings per share reported by Heska Corp for the previous quarter, Wall Street now forecasts -25.71% negative EPS growth.

Heska Corp (NASDAQ:HSKA) Ratings Coverage

Out of 2 analysts covering Heska Corp (NASDAQ:HSKA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Heska Corp has been the topic of 3 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by CL King given on Friday, April 1. On Thursday, August 4 the stock rating was downgraded by Gabelli to “Hold”. The stock of Heska Corp (NASDAQ:HSKA) has “Hold” rating given on Tuesday, August 25 by TheStreet.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

Insitutional Activity: The institutional sentiment increased to 1.54 in Q2 2016. Its up 0.10, from 1.44 in 2016Q1. The ratio improved, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.
The Massachusetts-based Geode Management Lc has invested 0% in Heska Corp (NASDAQ:HSKA). Parametric Port Assocs Ltd Liability Corporation holds 14,909 shares or 0% of its portfolio. Blackrock reported 5,095 shares or 0% of all its holdings. Bank Of America De last reported 0% of its portfolio in the stock. American Century Companies holds 9,474 shares or 0% of its portfolio. Manufacturers Life Insurance The holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 4,711 shares. Moreover, Raymond James Trust Na has 0.04% invested in Heska Corp (NASDAQ:HSKA) for 13,000 shares. Loomis Sayles Com Lp has 0% invested in the company for 97 shares. Moreover, Art Advsr Ltd Liability has 0.02% invested in Heska Corp (NASDAQ:HSKA) for 8,544 shares. Wedge Capital Mngmt L Ltd Partnership Nc last reported 8,500 shares in the company. Bogle Inv Limited Partnership De has invested 0.11% of its portfolio in Heska Corp (NASDAQ:HSKA). Prudential Fincl has 22,650 shares for 0% of their US portfolio. Jpmorgan Chase And Co holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 50 shares. The New York-based Highbridge Mgmt Ltd Com has invested 0% in Heska Corp (NASDAQ:HSKA). Vanguard Gp Inc last reported 226,843 shares in the company.

Insider Transactions: Since May 10, 2016, the stock had 0 buys, and 13 selling transactions for $5.64 million net activity. $879 worth of Heska Corp (NASDAQ:HSKA) shares were sold by Wilson Kevin S.. 5,000 Heska Corp (NASDAQ:HSKA) shares with value of $262,642 were sold by NAPOLITANO JASON A. On Wednesday, August 24 McMahon John sold $7,028 worth of the stock or 137 shares. McGinley Michael J had sold 5,998 shares worth $218,927 on Tuesday, May 10. The insider Asakowicz Steve sold 4,698 shares worth $246,864.

More news for Heska Corp (NASDAQ:HSKA) were recently published by: Marketwatch.com, which released: “Heska downgraded to neutral from buy at B. Riley” on December 21, 2009. Quotes.Wsj.com‘s article titled: “News Heska Corp.HSKA” and published on February 12, 2011 is yet another important article.

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment